Sanofi $SNY Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its stake in Sanofi (NASDAQ:SNY) by 39.0% during the 3rd quarter, Holdings Channel reports. The fund owned 535,527 shares of the company’s stock after acquiring an additional 150,198 shares during the period. Russell Investments Group Ltd.’s holdings in Sanofi were worth $25,277,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Schroder Investment Management Group purchased a new stake in Sanofi during the 3rd quarter worth about $5,661,000. Private Advisor Group LLC lifted its holdings in Sanofi by 9.2% in the 3rd quarter. Private Advisor Group LLC now owns 80,316 shares of the company’s stock valued at $3,791,000 after purchasing an additional 6,782 shares in the last quarter. ProVise Management Group LLC lifted its holdings in Sanofi by 5.1% in the 3rd quarter. ProVise Management Group LLC now owns 210,531 shares of the company’s stock valued at $9,937,000 after purchasing an additional 10,135 shares in the last quarter. Regal Partners Ltd boosted its stake in shares of Sanofi by 7.1% during the 3rd quarter. Regal Partners Ltd now owns 1,657,539 shares of the company’s stock worth $78,236,000 after purchasing an additional 109,335 shares during the last quarter. Finally, Guardian Partners Inc. boosted its stake in shares of Sanofi by 0.4% during the 3rd quarter. Guardian Partners Inc. now owns 182,446 shares of the company’s stock worth $9,079,000 after purchasing an additional 698 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Guggenheim downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Barclays lowered Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Sanofi currently has a consensus rating of “Hold” and an average target price of $62.67.

Sanofi Price Performance

Sanofi stock opened at $43.63 on Friday. The firm has a fifty day moving average of $46.94 and a 200-day moving average of $48.28. Sanofi has a 52-week low of $43.34 and a 52-week high of $59.17. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $106.41 billion, a P/E ratio of 12.12, a PEG ratio of 1.13 and a beta of 0.45.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.